Table 1.
Demographic and clinicopathological characteristics of all patients.
| All patients (n = 264) | |
|---|---|
| Age (years), mean ± SD) | 48.69 ± 9.78 |
| FIGO 2009 staging, n (%) | |
| I | 142 (53.79) |
| II | 104 (39.39) |
| III | 13 (4.92) |
| IV | 5 (1.89) |
| Staging categories, n (%) | |
| Early | 104 (39.39) |
| Locally advanced | 142 (53.79) |
| Advanced | 18 (6.82) |
| Histological subtypes, n (%) | |
| SCC | 209 (79.17) |
| ADC | 46 (17.42) |
| Adenosquamous carcinoma | 9 (3.41) |
| Histological differentiation, n (%) | |
| Grade 1 | 20 (12.35) |
| Grade 2 | 79 (48.77) |
| Grade 3 | 63 (38.89) |
| Primary treatment regimens, n (%) | |
| Only chemotherapy | 1 (0.38) |
| Only radiotherapy or CCRT | 74 (28.03) |
| Radiotherapy or CCRT plus chemotherapy | 13 (4.92) |
| Surgery with/without adjuvant therapy | 176 (66.67) |
| DFS (months), median (range) | 16.87 (3.1–249.6) |
| Recurrent sites, n (%) | |
| Only within pelvic cavity | 134 (50.76) |
| Only beyond pelvic cavity | 48 (18.18) |
| Both within and beyond pelvic cavity | 82 (31.06) |
| Number of recurrent sites, n (%) | |
| Solitary | 57 (21.59) |
| Multiple | 207 (78.41) |
| Diagnostic regimens, n (%) | |
| Symptoms | 117 (44.32) |
| Physical examination | 33 (12.50) |
| Cervical cytology with/without hrHPV | 4 (1.52) |
| Serum biomarker | 34 (12.88) |
| Imaging | 76 (28.79) |
| Pathological evidences of recurrence, n (%) | |
| No | 101 (38.26) |
| Yes | 163 (61.74) |
ADC, adenocarcinoma; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; FIGO, the International Federation of Gynecology and Obstetrics; hrHPV, high-risk human papillomavirus; SCC, squamous cell carcinoma; SD, standard deviation.